Cargando…
CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer
The prognostic influence of CA 125 regression between the time point before surgery and after two completed courses of chemotherapy was studied in 210 patients with advanced ovarian cancer, and was compared to other well established prognostic factors. CA 125 blood samples were collected preoperativ...
Autores principales: | Peters-Engl, C, Obermair, A, Heinzl, H, Buxbaum, P, Sevelda, P, Medl, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362892/ https://www.ncbi.nlm.nih.gov/pubmed/10574252 http://dx.doi.org/10.1038/sj.bjc.6690744 |
Ejemplares similares
-
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001) -
TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
por: Medl, M., et al.
Publicado: (1995) -
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
por: Menon, U, et al.
Publicado: (1999) -
Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis
por: Guo, Junhong, et al.
Publicado: (2017) -
Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer
por: Lee, Maria, et al.
Publicado: (2016)